160 related articles for article (PubMed ID: 34949662)
1. Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.
Nastase A; Dima SO; Lupo A; Laszlo V; Tagett R; Draghici S; Georgescu ME; Nechifor A; Berbece S; Popescu I; Alifano M; Klepetko W; Grigoroiu M
Cancer Genomics Proteomics; 2022; 19(1):94-104. PubMed ID: 34949662
[TBL] [Abstract][Full Text] [Related]
2. Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes.
Nastase A; Lupo A; Laszlo V; Damotte D; Dima S; Canny E; Alifano M; Popescu I; Klepetko W; Grigoroiu M
Cancer Genomics Proteomics; 2020; 17(5):587-595. PubMed ID: 32859637
[TBL] [Abstract][Full Text] [Related]
3. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
Duan H; Liang L; Xie S; Wang C
BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
[TBL] [Abstract][Full Text] [Related]
4. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
5. Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer.
Drake JA; Portnoy DC; Tauer K; Weksler B
Ann Thorac Surg; 2018 Oct; 106(4):959-965. PubMed ID: 29856974
[TBL] [Abstract][Full Text] [Related]
6. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers.
Misumi K; Harada H; Tsubokawa N; Tsutani Y; Matsumoto K; Miyata Y; Yamashita Y; Okada M
Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):392-399. PubMed ID: 28432576
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
10. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
11. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
14. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
[TBL] [Abstract][Full Text] [Related]
15. Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer.
Carretta A; Ciriaco P; Melloni G; Sayed I; Bandiera A; Ferla L; Puglisi A; Zannini P
World J Surg; 2008 Dec; 32(12):2636-42. PubMed ID: 18836761
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).
Reymen B; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
Radiother Oncol; 2014 Mar; 110(3):482-7. PubMed ID: 24444527
[TBL] [Abstract][Full Text] [Related]
19. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
20. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Kappers I; van Sandick JW; Burgers SA; Belderbos JS; van Zandwijk N; Klomp HM
Lung Cancer; 2010 May; 68(2):222-7. PubMed ID: 19664843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]